Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Ann M. Hanly Sells 2,711 Shares

Vir Biotechnology, Inc. (NASDAQ:VIRGet Free Report) EVP Ann M. Hanly sold 2,711 shares of the firm’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $10.05, for a total value of $27,245.55. Following the completion of the transaction, the executive vice president now owns 132,069 shares of the company’s stock, valued at $1,327,293.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Vir Biotechnology Stock Down 5.7 %

Shares of Vir Biotechnology stock traded down $0.58 on Tuesday, reaching $9.62. The company’s stock had a trading volume of 999,243 shares, compared to its average volume of 1,092,915. The company has a market capitalization of $1.30 billion, a P/E ratio of -2.10 and a beta of 0.41. Vir Biotechnology, Inc. has a 52-week low of $7.72 and a 52-week high of $27.48. The stock has a 50-day moving average price of $10.20 and a 200-day moving average price of $9.66.

Vir Biotechnology (NASDAQ:VIRGet Free Report) last issued its quarterly earnings results on Thursday, February 22nd. The company reported ($0.86) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.28. The firm had revenue of $16.80 million for the quarter, compared to analyst estimates of $11.18 million. Vir Biotechnology had a negative return on equity of 34.92% and a negative net margin of 713.69%. The business’s revenue was down 66.0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.76) earnings per share. Sell-side analysts forecast that Vir Biotechnology, Inc. will post -4.04 earnings per share for the current fiscal year.

Institutional Trading of Vir Biotechnology

Institutional investors have recently made changes to their positions in the company. Perceptive Advisors LLC boosted its stake in Vir Biotechnology by 1,277.2% during the second quarter. Perceptive Advisors LLC now owns 1,958,264 shares of the company’s stock worth $48,036,000 after buying an additional 1,816,070 shares during the last quarter. Vanguard Group Inc. boosted its stake in Vir Biotechnology by 21.1% during the third quarter. Vanguard Group Inc. now owns 9,928,416 shares of the company’s stock worth $191,420,000 after buying an additional 1,731,172 shares during the last quarter. State Street Corp boosted its stake in Vir Biotechnology by 65.9% during the first quarter. State Street Corp now owns 4,193,764 shares of the company’s stock worth $107,864,000 after buying an additional 1,665,657 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Vir Biotechnology by 2,167.7% during the second quarter. Dimensional Fund Advisors LP now owns 1,022,739 shares of the company’s stock worth $25,091,000 after buying an additional 977,639 shares during the last quarter. Finally, Norges Bank purchased a new stake in Vir Biotechnology in the fourth quarter valued at $18,440,000. 65.32% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently weighed in on VIR. HC Wainwright reiterated a “buy” rating and set a $110.00 price target on shares of Vir Biotechnology in a research report on Friday, March 15th. JPMorgan Chase & Co. lifted their price target on Vir Biotechnology from $9.00 to $10.00 and gave the company a “neutral” rating in a research report on Friday, February 23rd. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Vir Biotechnology has a consensus rating of “Moderate Buy” and a consensus target price of $34.38.

Read Our Latest Report on VIR

About Vir Biotechnology

(Get Free Report)

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand.

Recommended Stories

Insider Buying and Selling by Quarter for Vir Biotechnology (NASDAQ:VIR)

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.